SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.
Leuk Res
; 36(4): 459-66, 2012 Apr.
Article
en En
| MEDLINE
| ID: mdl-21885123
ABSTRACT
By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Leucemia Linfocítica Crónica de Células B
/
Protocolos de Quimioterapia Combinada Antineoplásica
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Leuk Res
Año:
2012
Tipo del documento:
Article
País de afiliación:
Italia